I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience CMSC 2023
Roche and Genentech at

CMSC 2023

May 31 - June 03
Aurora, USA
cmscscholar.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Jun 1 / Roche and Genentech
Long-term Efficacy of Satralizumab▼ in Adults With Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon
This study presents the long-term efficacy of satralizumab▼ in adult patients with AQP4-IgG+ NMOSD who rolled over from the SAkuraSky and SAkuraStar studies into the single-arm, open-label study SAkuraMoon.
Neuroscience Neuromyelitis Optica CMSC-2023

Sign up or login to unlock the full suite of MEDICALLY features
May 31 / Roche and Genentech
Clinical simulation as a novel approach to evaluate digital health solutions: Floodlight MS case study
There is growing demand for agile methods to rapidly learn how digital solutions can play a role in clinical practice. Clinical simulation is a pragmatic approach to generate evidence quickly by collecting data from end users as they perform tasks in realistic clinical scenarios. Two high-fidelity patient cases consisting of clinical notes, imaging reports and Floodlight™ MS data were developed with input from expert neurologists to explore clinical simulation as a method for evaluating Floodlight MS in routine multiple sclerosis (MS) care, such as identifying patient concerns and making care decisions.
Neuroscience Multiple Sclerosis CMSC-2023

Sign up or login to unlock the full suite of MEDICALLY features
May 28 / Roche and Genentech
Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second-Line Treatment With Ocrelizumab▼
Research has demonstrated that early use of ocrelizumab▼ (OCR), a high-efficacy disease-modifying therapy (DMT), can reduce relapses and delay progression, which is associated with reduced costs, in persons with multiple sclerosis (pwMS). However, there is limited real-world evidence on the impact of first-line OCR on clinical and economic outcomes. This study evaluated differences in events often associated with a relapse (EAR), healthcare resource use (HCRU), and costs among pwMS who initiated OCR as a first (1L) vs second or later line (2L+) DMT following MS diagnosis.
Neuroscience Multiple Sclerosis CMSC-2023
04:20 PM
Duration 20mins Gaylord Rockies Resort & Convention Center Summit 6-7
Long-term Efficacy of Satralizumab▼ in Adults With Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon
Anthony Traboulsee, Ingo Kleiter, Jacqueline Palace, Kazuo Fujihara, Albert Saiz, Ivana Vodopivec, Gaelle Klingelschmitt, Carole Marcillat, Jeffrey L Bennett
Neuroscience | Neuromyelitis Optica

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.